3 best performing ASX shares in the week of 10 October 2022
Marc Kennis, October 17, 2022
The 3 best performing ASX shares in the week of 3 October 2022
The 3 best performing ASX shares of the week starting 10 October 2022 were Cettire (ASX:CTT), up 46.4%, Nova Eye Medical (ASX:EYE), up 42.5%, and Element 25 (ASX:E25), up 34.2%.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
1. Cettire (ASX:CTT)
Industry: Consumer Discretionary
Cettire Limited (ASX:CTT) is a global online retailer, offering a selection of in-demand personal luxury goods via its website, cettire.com. Cettire has access to a catalogue of over 1,700 luxury brands and over 190,000 products of clothing, shoes, bags and accessories.
Market Cap: $505m
12 month high / low: $0.33 – $4.81
2. Nova Eye Medical (ASX:EYE)
Industry: Healthcare
Nova Eye Medical Limited (ASX:EYE, formerly Ellex Medical Lasers Limited) is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices.
Market Cap: $42m
12 month high / low: $0.18 – $0.42
3. Element 25 (ASX:E25)
Industry: Resources
Element 25 Limited (ASX:E25, formerly Montezuma Mining Company Ltd) rounds out the top 3 best performing ASX shares this week. E25 is a mineral exploration and mining company exploring for manganese, copper and gold deposits in Western Australia. The Company has a 100% interest in Yamarna Gold Project, Butcherbird Manganese-Copper Project and Green Dam Project.
Market Cap: $159m
12 month high / low: $0.425 – $2.05
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Analysts aren’t optimistic about iron ore prices in 2025, will they be right and what will it mean for iron ore stocks?
In which direction will iron ore prices in 2025 go? Chinese trade data would suggest upwards, and indeed prices jumped…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India
Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…